Vaccination News

The FDA has approved Capvaxive, Merck’s 21-valent pneumococcal vaccine, which is specifically made to protect adults.

Together, a group of viruses nicknamed “FLiRT” have emerged to become the most common SARS-CoV-2 variants in the country.

The FDA has approved Merck’s 21-valent pneumococcal vaccine, which is specifically made for adults, the company announced.

Moderna announced positive phase 3 trial data for its combination COVID-19 and influenza vaccine this week, suggesting a combination shot for respiratory infections is on the way.

COVID-19 mitigation measures disrupted the circulation of respiratory syncytial virus, leading to atypical season in 2021 and 2022 that saw higher rates of hospitalization among young children, according to research published in Pediatrics.

In late May, the FDA announced approval of Moderna's mResvia, marking the third vaccine approved for respiratory syncytial virus and first time messenger RNA technology has been used for preventing a disease other than COVID-19.

The CDC announced a Salmonella outbreak that has spread to 25 states and left 162 people sick and 54 hospitalized was likely caused by recalled cucumbers.

Children in Massachusetts who were publicly insured or living in less affluent ZIP codes were less likely to receive nirsevimab, a monoclonal antibody for respiratory syncytial virus, according to research published in Pediatrics.

Many immigrant communities are at risk for outbreaks of vaccine-preventable diseases because of low and declining vaccination coverage, according to findings published in Pediatrics.

A third human case in the avian influenza outbreak has been confirmed in another Michigan dairy worker, although risk to the general public remains low, according to the CDC.